ABSTRACT
Background CD4 T cell phenotyping-based blood assays have the potential to meet WHO target product profiles (TPP) of non-sputum-biomarker-based tests to diagnose tuberculosis (TB). Yet, substantial refinements are required to allow their implementation in clinical settings. This study assessed the real time performance of a simplified T cell activation marker (TAM)-TB assay to detect TB in adults from one millilitre of blood with a 24h turnaround time.
Methods We recruited 479 GeneXpert® positive cases and 108 symptomatic but GeneXpert® negative controls from presumptive adult TB patients in the Temeke District of Dar-es-Salaam, Tanzania. TAM-TB assay accuracy was assessed by comparison with a composite reference standard comprising GeneXpert® and solid culture. A single millilitre of fresh blood was processed to measure expression of CD38 or CD27 by CD4 T cells producing INF-γ and/or TNF-α in response to a synthetic peptide pool covering the sequences of Mycobacterium tuberculosis (Mtb) ESAT-6, CFP-10 and TB10.4 antigens on a 4-color FACSCalibur apparatus.
Results Significantly superior to CD27 in accurately diagnosing TB, the CD38-based TAM-TB assay specificity reached 93.4% for a sensitivity of 82.2% with an area under the receiver operating characteristics curve of 0.87 (95% CI 0.84-0.91). The assay performance was not significantly affected by HIV status.
Conclusions We successfully implemented TAM-TB immunoassay routine testing with a 24h turnaround time at district level in a resource limited setting. Starting from one millilitre of fresh blood and being not influenced by HIV status, TAM-TB assay format and performance appears closely compatible with the optimal TPP accuracy criteria defined by WHO for a non-sputum confirmatory TB test.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Swiss National Science Foundation (Sinergia grant 177163). Hellen Hiza PhD fellowship was provided by the education department of Basel city canton .
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the institutional review board of the Ifakara Health Institute, the Medical Research Coordinating Committee of the National Institute of Medical Research in Tanzania and the Ethics Committee Northwest and Central Switzerland.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
TB DAR cohort study constitutes an observational study that did not require submission to TMDA but an ethical clearance was obtained as detailed above. The data used in this manuscript are not publicly available due to the Tanzania national policy on data sharing. Data will be made available upon request where concerned parties will sign a data transfer agreement approved by the Medical Research Coordinating Committee.
List of abbreviations
- ART
- Antiretroviral therapy
- AUC
- Area under the curve
- BMI
- body mass index
- Ct
- cycle threshold
- NTLP
- National Tuberculosis and Leprosy Program
- PBMC
- Peripheral Blood Mononuclear Cells
- RIF
- Rifampicin
- TAM
- T cell activation marker
- TB
- tuberculosis
- TPP
- target product profiles
